Omeros (NASDAQ:OMER) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery. Omidria is marketed in the United States through a partnership with Mallinckrodt Pharmaceuticals, with additional regulatory filings underway in selected international markets. The approval and commercialization of Omidria marked the company’s transition from a pure-research organization to a commercial stage biopharma company.
The company’s lead clinical candidate, narsoplimab (OMS721), is a human monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of complement activation. Narsoplimab is being evaluated in rare, life-threatening disorders such as hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA) and IgA nephropathy. In addition, Omeros has several small-molecule programs in development, including P2X7 receptor antagonists for neuropathic pain and addiction and selective kappa opioid receptor modulators for mood disorders.
Headquartered in Seattle, Washington, Omeros was founded in 1994 and completed its initial public offering in 2010. Under the leadership of founder and CEO Gregory A. Demopulos, M.D., the company has grown to include research and development facilities in both the United States and Europe, supporting global clinical trials and regulatory activities. Omeros continues to expand its pipeline through in-house discovery efforts and strategic collaborations aimed at bringing novel therapies to patients worldwide.
